Irritable Bowel Syndrome (IBS) Therapeutics Market Report

Europe Irritable Bowel Syndrome (IBS) Therapeutics Market Size, Status and Forecast 2014-2026

  • POSTDATE：Jan 24, 2020
  • PAGES：180
  • REPORT CODE：GMM447111
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The Irritable Bowel Syndrome (IBS) Therapeutics market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 4.9% during the forecast period. Focusing on the Europe market, this report analyzes the specific consumption structure, such as types and end users. In order to present the status of the circulation of this product in different Europe countries, this report covers top export and import countries to confirm the potential markets. Leading countries such as Germany, UK, France, Italy, Spain, Poland, Russia, Switzerland, Turkey, Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden), Benelux (Belgium, Netherlands, and Luxembourg), Baltic States (Estonia, Latvia, and Lithuania) and other countries, the market status and consumption potential of these countries are covered in the research, providing valuable opinions of strategic adjustments for existing groups and new entrants.

    The Snapshot of Europe Irritable Bowel Syndrome (IBS) Therapeutics Market Segmentations:

    By Player:

    • Ironwood Pharmaceuticals

    • Astellas Pharma

    • Novartis

    • Synergy Pharmaceuticals

    • Abbott Laboratories

    • Valeant Pharmaceuticals International

    • GlaxoSmithKline

    • Sucampo Pharmaceuticals

    • Ardelyx

    By Type:

    • Blautix (Strain)

    • Bekinda (IBS-D)

    • SYN-010

    • Tenapanor

    By End-User:

    • Hospital

    • Research

    By Region:

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Poland

    • Russia

    • Switzerland

    • Turkey

    • Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden)

      • Denmark

      • Finland

      • Norway

      • Sweden

      • Iceland

    • Benelux (Belgium, Netherlands, and Luxembourg)

      • Belgium

      • Netherlands

      • Luxembourg

    • Baltic States (Estonia, Latvia, and Lithuania)

      • Estonia

      • Latvia

      • Lithuania

  • Table of Contents

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Irritable Bowel Syndrome (IBS) Therapeutics Market

    • 1.3 Market Segment by Type

    • 1.3.1 Europe Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate of Blautix (Strain) from 2014 to 2026

    • 1.3.2 Europe Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate of Bekinda (IBS-D) from 2014 to 2026

    • 1.3.3 Europe Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate of SYN-010 from 2014 to 2026

    • 1.3.4 Europe Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate of Tenapanor from 2014 to 2026

    • 1.4 Market Segment by Application

    • 1.4.1 Europe Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate of Hospital from 2014 to 2026

    • 1.4.2 Europe Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate of Research from 2014 to 2026

    • 1.5 Market Segment by Regions

      • 1.5.1 Germany Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate from 2014 to 2026

      • 1.5.2 UK Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate from 2014 to 2026

      • 1.5.3 France Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate from 2014 to 2026

      • 1.5.4 Italy Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate from 2014 to 2026

      • 1.5.5 Spain Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate from 2014 to 2026

      • 1.5.6 Poland Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate from 2014 to 2026

      • 1.5.7 Russia Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate from 2014 to 2026

      • 1.5.8 Switzerland Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate from 2014 to 2026

      • 1.5.9 Turkey Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate from 2014 to 2026

      • 1.5.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate from 2014 to 2026

      • 1.5.11 Benelux (Belgium, Netherlands, and Luxembourg) Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate from 2014 to 2026

      • 1.5.12 Baltic States (Estonia, Latvia, and Lithuania) Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate from 2014 to 2026

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    3 Segmentation of Irritable Bowel Syndrome (IBS) Therapeutics Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Venders

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Irritable Bowel Syndrome (IBS) Therapeutics by Major Types

      • 3.4.1 Market Size and Growth Rate of Blautix (Strain)

      • 3.4.2 Market Size and Growth Rate of Bekinda (IBS-D)

      • 3.4.3 Market Size and Growth Rate of SYN-010

      • 3.4.4 Market Size and Growth Rate of Tenapanor

    4 Segmentation of Irritable Bowel Syndrome (IBS) Therapeutics Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Irritable Bowel Syndrome (IBS) Therapeutics by Major End-Users

      • 4.4.1 Market Size and Growth Rate of Irritable Bowel Syndrome (IBS) Therapeutics for Hospital

      • 4.4.2 Market Size and Growth Rate of Irritable Bowel Syndrome (IBS) Therapeutics for Research

    5 Market Analysis by Major Regions

    • 5.1 Europe Irritable Bowel Syndrome (IBS) Therapeutics Production Analysis by Top Regions

    • 5.2 Europe Irritable Bowel Syndrome (IBS) Therapeutics Consumption Analysis by Top Regions

    • 5.3 Europe Irritable Bowel Syndrome (IBS) Therapeutics Production, Import, Consumption and Export Analysis by Regions

      • 5.3.1 Germany Irritable Bowel Syndrome (IBS) Therapeutics Production, Import, Consumption and Export Analysis

      • 5.3.2 UK Irritable Bowel Syndrome (IBS) Therapeutics Production, Import, Consumption and Export Analysis

      • 5.3.3 France Irritable Bowel Syndrome (IBS) Therapeutics Production, Import, Consumption and Export Analysis

      • 5.3.4 Italy Irritable Bowel Syndrome (IBS) Therapeutics Production, Import, Consumption and Export Analysis

      • 5.3.5 Spain Irritable Bowel Syndrome (IBS) Therapeutics Production, Import, Consumption and Export Analysis

      • 5.3.6 Poland Irritable Bowel Syndrome (IBS) Therapeutics Production, Import, Consumption and Export Analysis

      • 5.3.7 Russia Irritable Bowel Syndrome (IBS) Therapeutics Production, Import, Consumption and Export Analysis

      • 5.3.8 Switzerland Irritable Bowel Syndrome (IBS) Therapeutics Production, Import, Consumption and Export Analysis

      • 5.3.9 Turkey Irritable Bowel Syndrome (IBS) Therapeutics Production, Import, Consumption and Export Analysis

      • 5.3.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Irritable Bowel Syndrome (IBS) Therapeutics Production, Import, Consumption and Export Analysis

      • 5.3.11 Benelux (Belgium, Netherlands, and Luxembourg) Irritable Bowel Syndrome (IBS) Therapeutics Production, Import, Consumption and Export Analysis

      • 5.3.12 Baltic States (Estonia, Latvia, and Lithuania) Irritable Bowel Syndrome (IBS) Therapeutics Production, Import, Consumption and Export Analysis

    6 Product Circulation of Irritable Bowel Syndrome (IBS) Therapeutics Market among Top Countries

    • 6.1 Top 5 Export Countries in Irritable Bowel Syndrome (IBS) Therapeutics Market from 2014 to 2019

      • 6.1.1 Top 5 Export Countries’ Export Value Analysis in Irritable Bowel Syndrome (IBS) Therapeutics Market from 2014 to 2019

      • 6.1.2 Top 5 Export Countries’ Export Volume Analysis in Irritable Bowel Syndrome (IBS) Therapeutics Market from 2014 to 2019

    • 6.2 Top 5 Import Countries in Irritable Bowel Syndrome (IBS) Therapeutics Market from 2014 to 2019

      • 6.2.1 Top 5 Import Countries’ Import Value Analysis in Irritable Bowel Syndrome (IBS) Therapeutics Market from 2014 to 2019

      • 6.2.2 Top 5 Import Countries’ Import Volume Analysis in Irritable Bowel Syndrome (IBS) Therapeutics Market from 2014 to 2019

    • 6.3 Emerging Top 3 Export Countries Analysis

    • 6.4 Emerging Top 3 Import Countries Analysis

    7. Germany Irritable Bowel Syndrome (IBS) Therapeutics Landscape Analysis

    • 7.1 Germany Irritable Bowel Syndrome (IBS) Therapeutics Landscape Analysis by Major Types

    • 7.2 Germany Irritable Bowel Syndrome (IBS) Therapeutics Landscape Analysis by Major End-Users

    8. UK Irritable Bowel Syndrome (IBS) Therapeutics Landscape Analysis

    • 8.1 UK Irritable Bowel Syndrome (IBS) Therapeutics Landscape Analysis by Major Types

    • 8.2 UK Irritable Bowel Syndrome (IBS) Therapeutics Landscape Analysis by Major End-Users

    9. France Irritable Bowel Syndrome (IBS) Therapeutics Landscape Analysis

    • 9.1 France Irritable Bowel Syndrome (IBS) Therapeutics Landscape Analysis by Major Types

    • 9.2 France Irritable Bowel Syndrome (IBS) Therapeutics Landscape Analysis by Major End-Users

    10. Italy Irritable Bowel Syndrome (IBS) Therapeutics Landscape Analysis

    • 10.1 Italy Irritable Bowel Syndrome (IBS) Therapeutics Landscape Analysis by Major Types

    • 10.2 Italy Irritable Bowel Syndrome (IBS) Therapeutics Landscape Analysis by Major End-Users

    11. Spain Irritable Bowel Syndrome (IBS) Therapeutics Landscape Analysis

    • 11.1 Spain Irritable Bowel Syndrome (IBS) Therapeutics Landscape Analysis by Major Types

    • 11.2 Spain Irritable Bowel Syndrome (IBS) Therapeutics Landscape Analysis by Major End-Users

    12. Poland Irritable Bowel Syndrome (IBS) Therapeutics Landscape Analysis

    • 12.1 Poland Irritable Bowel Syndrome (IBS) Therapeutics Landscape Analysis by Major Types

    • 12.2 Poland Irritable Bowel Syndrome (IBS) Therapeutics Landscape Analysis by Major End-Users

    13. Russia Irritable Bowel Syndrome (IBS) Therapeutics Landscape Analysis

    • 13.1 Russia Irritable Bowel Syndrome (IBS) Therapeutics Landscape Analysis by Major Types

    • 13.2 Russia Irritable Bowel Syndrome (IBS) Therapeutics Landscape Analysis by Major End-Users

    14. Switzerland Irritable Bowel Syndrome (IBS) Therapeutics Landscape Analysis

    • 14.1 Switzerland Irritable Bowel Syndrome (IBS) Therapeutics Landscape Analysis by Major Types

    • 14.2 Switzerland Irritable Bowel Syndrome (IBS) Therapeutics Landscape Analysis by Major End-Users

    15. Turkey Irritable Bowel Syndrome (IBS) Therapeutics Landscape Analysis

    • 15.1 Turkey Irritable Bowel Syndrome (IBS) Therapeutics Landscape Analysis by Major Types

    • 15.2 Turkey Irritable Bowel Syndrome (IBS) Therapeutics Landscape Analysis by Major End-Users

    16. Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Irritable Bowel Syndrome (IBS) Therapeutics Landscape Analysis

    • 16.1 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Irritable Bowel Syndrome (IBS) Therapeutics Landscape Analysis by Major Types

    • 16.2 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Irritable Bowel Syndrome (IBS) Therapeutics Landscape Analysis by Major End-Users

    • 16.3 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Irritable Bowel Syndrome (IBS) Therapeutics Landscape Analysis by Top Countries

      • 16.3.1 Denmark Irritable Bowel Syndrome (IBS) Therapeutics Market Volume and Growth Rate

      • 16.3.2 Finland Irritable Bowel Syndrome (IBS) Therapeutics Market Volume and Growth Rate

      • 16.3.3 Norway Irritable Bowel Syndrome (IBS) Therapeutics Market Volume and Growth Rate

      • 16.3.4 Sweden Irritable Bowel Syndrome (IBS) Therapeutics Market Volume and Growth Rate

      • 16.3.6 Iceland Irritable Bowel Syndrome (IBS) Therapeutics Market Volume and Growth Rate

    17 Benelux (Belgium, Netherlands, and Luxembourg) Irritable Bowel Syndrome (IBS) Therapeutics Landscape Analysis

    • 17.1 Benelux (Belgium, Netherlands, and Luxembourg) Irritable Bowel Syndrome (IBS) Therapeutics Landscape Analysis by Major Types

    • 17.2 Benelux (Belgium, Netherlands, and Luxembourg) Irritable Bowel Syndrome (IBS) Therapeutics Landscape Analysis by Major End-Users

    • 17.3 Benelux (Belgium, Netherlands, and Luxembourg) Irritable Bowel Syndrome (IBS) Therapeutics Landscape Analysis by Top Countries

      • 17.3.1 Belgium Irritable Bowel Syndrome (IBS) Therapeutics Market Volume and Growth Rate

      • 17.3.2 Netherlands Irritable Bowel Syndrome (IBS) Therapeutics Market Volume and Growth Rate

      • 17.3.3 Luxembourg Irritable Bowel Syndrome (IBS) Therapeutics Market Volume and Growth Rate

    18 Baltic States (Estonia, Latvia, and Lithuania) Irritable Bowel Syndrome (IBS) Therapeutics Landscape Analysis

    • 18.1 Baltic States (Estonia, Latvia, and Lithuania) Irritable Bowel Syndrome (IBS) Therapeutics Landscape Analysis by Major Types

    • 18.2 Baltic States (Estonia, Latvia, and Lithuania) Irritable Bowel Syndrome (IBS) Therapeutics Landscape Analysis by Major End-Users

    • 18.3 Baltic States (Estonia, Latvia, and Lithuania) Irritable Bowel Syndrome (IBS) Therapeutics Landscape Analysis by Top Countries

      • 18.3.1 Estonia Irritable Bowel Syndrome (IBS) Therapeutics Market Volume and Growth Rate

      • 18.3.2 Latvia Irritable Bowel Syndrome (IBS) Therapeutics Market Volume and Growth Rate

      • 18.3.3 Lithuania Irritable Bowel Syndrome (IBS) Therapeutics Market Volume and Growth Rate

    19 Major Players Profiles

    • 19.1 Ironwood Pharmaceuticals

      • 19.1.1 Ironwood Pharmaceuticals Company Profile and Development Status

      • 19.1.2 Market Performance

      • 19.1.3 Product and Service Introduction

    • 19.2 Astellas Pharma

      • 19.2.1 Astellas Pharma Company Profile and Development Status

      • 19.2.2 Market Performance

      • 19.2.3 Product and Service Introduction

    • 19.3 Novartis

      • 19.3.1 Novartis Company Profile and Development Status

      • 19.3.2 Market Performance

      • 19.3.3 Product and Service Introduction

    • 19.4 Synergy Pharmaceuticals

      • 19.4.1 Synergy Pharmaceuticals Company Profile and Development Status

      • 19.4.2 Market Performance

      • 19.4.3 Product and Service Introduction

    • 19.5 Abbott Laboratories

      • 19.5.1 Abbott Laboratories Company Profile and Development Status

      • 19.5.2 Market Performance

      • 19.5.3 Product and Service Introduction

    • 19.6 Valeant Pharmaceuticals International

      • 19.6.1 Valeant Pharmaceuticals International Company Profile and Development Status

      • 19.6.2 Market Performance

      • 19.6.3 Product and Service Introduction

    • 19.7 GlaxoSmithKline

      • 19.7.1 GlaxoSmithKline Company Profile and Development Status

      • 19.7.2 Market Performance

      • 19.7.3 Product and Service Introduction

    • 19.8 Sucampo Pharmaceuticals

      • 19.8.1 Sucampo Pharmaceuticals Company Profile and Development Status

      • 19.8.2 Market Performance

      • 19.8.3 Product and Service Introduction

    • 19.9 Ardelyx

      • 19.9.1 Ardelyx Company Profile and Development Status

      • 19.9.2 Market Performance

      • 19.9.3 Product and Service Introduction

    The List of Tables and Figures (Totals 92 Figures and 123 Tables)

    • Figure Product Picture

    • Figure Europe Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate of Blautix (Strain) from 2014 to 2026

    • Figure Europe Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate of Bekinda (IBS-D) from 2014 to 2026

    • Figure Europe Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate of SYN-010 from 2014 to 2026

    • Figure Europe Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate of Tenapanor from 2014 to 2026

    • Figure Europe Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate of Hospital from 2014 to 2026

    • Figure Europe Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate of Research from 2014 to 2026

    • Figure Germany Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure UK Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure France Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Italy Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Spain Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Poland Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Russia Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Switzerland Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Turkey Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Canada Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Mexico Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Denmark Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Finland Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Norway Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Sweden Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Iceland Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Benelux (Belgium, Netherlands, and Luxembourg) Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Belgium Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Netherlands Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Luxembourg Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Baltic States (Estonia, Latvia, and Lithuania) Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Estonia Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Latvia Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Lithuania Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Development Trends and Industry Dynamics of Irritable Bowel Syndrome (IBS) Therapeutics Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 6 Players from 2014 to 2019

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Table Specifications of Different Types of Irritable Bowel Syndrome (IBS) Therapeutics

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Irritable Bowel Syndrome (IBS) Therapeutics by Different Types from 2014 to 2026

    • Table Consumption Share of Irritable Bowel Syndrome (IBS) Therapeutics by Different Types from 2014 to 2026

    • Figure Market Size and Growth Rate of Blautix (Strain)

    • Figure Market Size and Growth Rate of Bekinda (IBS-D)

    • Figure Market Size and Growth Rate of SYN-010

    • Figure Market Size and Growth Rate of Tenapanor

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Table Consumption of Irritable Bowel Syndrome (IBS) Therapeutics by Different End-Users from 2014 to 2026

    • Table Consumption Share of Irritable Bowel Syndrome (IBS) Therapeutics by Different End-Users from 2014 to 2026

    • Figure Market Size and Growth Rate of Hospital

    • Figure Market Size and Growth Rate of Research

    • Table Europe Irritable Bowel Syndrome (IBS) Therapeutics Production by Major Regions

    • Table Europe Irritable Bowel Syndrome (IBS) Therapeutics Production Share by Major Regions

    • Figure Europe Irritable Bowel Syndrome (IBS) Therapeutics Production Share by Major Countries and Regions in 2014

    • Table Europe Irritable Bowel Syndrome (IBS) Therapeutics Consumption by Major Regions

    • Table Europe Irritable Bowel Syndrome (IBS) Therapeutics Consumption Share by Major Regions

    • Table Germany Irritable Bowel Syndrome (IBS) Therapeutics Production, Import, Consumption and Export Analysis

    • Table UK Irritable Bowel Syndrome (IBS) Therapeutics Production, Import, Consumption and Export Analysis

    • Table France Irritable Bowel Syndrome (IBS) Therapeutics Production, Import, Consumption and Export Analysis

    • Table Italy Irritable Bowel Syndrome (IBS) Therapeutics Production, Import, Consumption and Export Analysis

    • Table Spain Irritable Bowel Syndrome (IBS) Therapeutics Production, Import, Consumption and Export Analysis

    • Table Poland Irritable Bowel Syndrome (IBS) Therapeutics Production, Import, Consumption and Export Analysis

    • Table Russia Irritable Bowel Syndrome (IBS) Therapeutics Production, Import, Consumption and Export Analysis

    • Table Switzerland Irritable Bowel Syndrome (IBS) Therapeutics Production, Import, Consumption and Export Analysis

    • Table Turkey Irritable Bowel Syndrome (IBS) Therapeutics Production, Import, Consumption and Export Analysis

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Irritable Bowel Syndrome (IBS) Therapeutics Production, Import, Consumption and Export Analysis

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Irritable Bowel Syndrome (IBS) Therapeutics Production, Import, Consumption and Export Analysis

    • Table Baltic States (Estonia, Latvia, and Lithuania) Irritable Bowel Syndrome (IBS) Therapeutics Production, Import, Consumption and Export Analysis

    • Table Top 5 Export Countries' Export Value Analysis in Irritable Bowel Syndrome (IBS) Therapeutics Market from 2014 to 2019

    • Table Top 5 Export Countries' Export Volume Analysis in Irritable Bowel Syndrome (IBS) Therapeutics Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Value Analysis in Irritable Bowel Syndrome (IBS) Therapeutics Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Volume Analysis in Irritable Bowel Syndrome (IBS) Therapeutics Market from 2014 to 2019

    • Figure Emerging Top 3 Export Countries Analysis

    • Figure Emerging Top 3 Import Countries Analysis

    • Table Germany Irritable Bowel Syndrome (IBS) Therapeutics Consumption by Types from 2014 to 2026

    • Table Germany Irritable Bowel Syndrome (IBS) Therapeutics Consumption Share by Types from 2014 to 2026

    • Table Germany Irritable Bowel Syndrome (IBS) Therapeutics Consumption by End-Users from 2014 to 2026

    • Table Germany Irritable Bowel Syndrome (IBS) Therapeutics Consumption Share by End-Users from 2014 to 2026

    • Table UK Irritable Bowel Syndrome (IBS) Therapeutics Consumption by Types from 2014 to 2026

    • Table UK Irritable Bowel Syndrome (IBS) Therapeutics Consumption Share by Types from 2014 to 2026

    • Table UK Irritable Bowel Syndrome (IBS) Therapeutics Consumption by End-Users from 2014 to 2026

    • Table UK Irritable Bowel Syndrome (IBS) Therapeutics Consumption Share by End-Users from 2014 to 2026

    • Table France Irritable Bowel Syndrome (IBS) Therapeutics Consumption by Types from 2014 to 2026

    • Table France Irritable Bowel Syndrome (IBS) Therapeutics Consumption Share by Types from 2014 to 2026

    • Table France Irritable Bowel Syndrome (IBS) Therapeutics Consumption by End-Users from 2014 to 2026

    • Table France Irritable Bowel Syndrome (IBS) Therapeutics Consumption Share by End-Users from 2014 to 2026

    • Table Italy Irritable Bowel Syndrome (IBS) Therapeutics Consumption by Types from 2014 to 2026

    • Table Italy Irritable Bowel Syndrome (IBS) Therapeutics Consumption Share by Types from 2014 to 2026

    • Table Italy Irritable Bowel Syndrome (IBS) Therapeutics Consumption by End-Users from 2014 to 2026

    • Table Italy Irritable Bowel Syndrome (IBS) Therapeutics Consumption Share by End-Users from 2014 to 2026

    • Table Spain Irritable Bowel Syndrome (IBS) Therapeutics Consumption by Types from 2014 to 2026

    • Table Spain Irritable Bowel Syndrome (IBS) Therapeutics Consumption Share by Types from 2014 to 2026

    • Table Spain Irritable Bowel Syndrome (IBS) Therapeutics Consumption by End-Users from 2014 to 2026

    • Table Spain Irritable Bowel Syndrome (IBS) Therapeutics Consumption Share by End-Users from 2014 to 2026

    • Table Poland Irritable Bowel Syndrome (IBS) Therapeutics Consumption by Types from 2014 to 2026

    • Table Poland Irritable Bowel Syndrome (IBS) Therapeutics Consumption Share by Types from 2014 to 2026

    • Table Poland Irritable Bowel Syndrome (IBS) Therapeutics Consumption by End-Users from 2014 to 2026

    • Table Poland Irritable Bowel Syndrome (IBS) Therapeutics Consumption Share by End-Users from 2014 to 2026

    • Table Russia Irritable Bowel Syndrome (IBS) Therapeutics Consumption by Types from 2014 to 2026

    • Table Russia Irritable Bowel Syndrome (IBS) Therapeutics Consumption Share by Types from 2014 to 2026

    • Table Russia Irritable Bowel Syndrome (IBS) Therapeutics Consumption by End-Users from 2014 to 2026

    • Table Russia Irritable Bowel Syndrome (IBS) Therapeutics Consumption Share by End-Users from 2014 to 2026

    • Table Switzerland Irritable Bowel Syndrome (IBS) Therapeutics Consumption by Types from 2014 to 2026

    • Table Switzerland Irritable Bowel Syndrome (IBS) Therapeutics Consumption Share by Types from 2014 to 2026

    • Table Switzerland Irritable Bowel Syndrome (IBS) Therapeutics Consumption by End-Users from 2014 to 2026

    • Table Switzerland Irritable Bowel Syndrome (IBS) Therapeutics Consumption Share by End-Users from 2014 to 2026

    • Table Turkey Irritable Bowel Syndrome (IBS) Therapeutics Consumption by Types from 2014 to 2026

    • Table Turkey Irritable Bowel Syndrome (IBS) Therapeutics Consumption Share by Types from 2014 to 2026

    • Table Turkey Irritable Bowel Syndrome (IBS) Therapeutics Consumption by End-Users from 2014 to 2026

    • Table Turkey Irritable Bowel Syndrome (IBS) Therapeutics Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Irritable Bowel Syndrome (IBS) Therapeutics Consumption by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Irritable Bowel Syndrome (IBS) Therapeutics Consumption Share by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Irritable Bowel Syndrome (IBS) Therapeutics Consumption by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Irritable Bowel Syndrome (IBS) Therapeutics Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Irritable Bowel Syndrome (IBS) Therapeutics Consumption by Major Countries from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Irritable Bowel Syndrome (IBS) Therapeutics Consumption Share by Major Countries from 2014 to 2026

    • Figure Denmark Irritable Bowel Syndrome (IBS) Therapeutics Market Volume and Growth Rate from 2014 to 2026

    • Figure Finland Irritable Bowel Syndrome (IBS) Therapeutics Market Volume and Growth Rate from 2014 to 2026

    • Figure Norway Irritable Bowel Syndrome (IBS) Therapeutics Market Volume and Growth Rate from 2014 to 2026

    • Figure Sweden Irritable Bowel Syndrome (IBS) Therapeutics Market Volume and Growth Rate from 2014 to 2026

    • Figure Iceland Irritable Bowel Syndrome (IBS) Therapeutics Market Volume and Growth Rate from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Irritable Bowel Syndrome (IBS) Therapeutics Consumption by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Irritable Bowel Syndrome (IBS) Therapeutics Consumption Share by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Irritable Bowel Syndrome (IBS) Therapeutics Consumption by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Irritable Bowel Syndrome (IBS) Therapeutics Consumption Share by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Irritable Bowel Syndrome (IBS) Therapeutics Consumption by Major Countries from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Irritable Bowel Syndrome (IBS) Therapeutics Consumption Share by Major Countries from 2014 to 2026

    • Figure Belgium Irritable Bowel Syndrome (IBS) Therapeutics Market Volume and Growth Rate from 2014 to 2026

    • Figure Netherlands Irritable Bowel Syndrome (IBS) Therapeutics Market Volume and Growth Rate from 2014 to 2026

    • Figure Luxembourg Irritable Bowel Syndrome (IBS) Therapeutics Market Volume and Growth Rate from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Irritable Bowel Syndrome (IBS) Therapeutics Consumption by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Irritable Bowel Syndrome (IBS) Therapeutics Consumption Share by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Irritable Bowel Syndrome (IBS) Therapeutics Consumption by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Irritable Bowel Syndrome (IBS) Therapeutics Consumption Share by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Irritable Bowel Syndrome (IBS) Therapeutics Consumption by Major Countries from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Irritable Bowel Syndrome (IBS) Therapeutics Consumption Share by Major Countries from 2014 to 2026

    • Figure Estonia Irritable Bowel Syndrome (IBS) Therapeutics Market Volume and Growth Rate from 2014 to 2026

    • Figure Latvia Irritable Bowel Syndrome (IBS) Therapeutics Market Volume and Growth Rate from 2014 to 2026

    • Figure Lithuania Countries Irritable Bowel Syndrome (IBS) Therapeutics Market Volume and Growth Rate from 2014 to 2026

    • Table Company Profile and Development Status of Ironwood Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Ironwood Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Ironwood Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Ironwood Pharmaceuticals

    • Table Product and Service Introduction of Ironwood Pharmaceuticals

    • Table Company Profile and Development Status of Astellas Pharma

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Astellas Pharma

    • Figure Sales and Growth Rate Analysis of Astellas Pharma

    • Figure Revenue and Market Share Analysis of Astellas Pharma

    • Table Product and Service Introduction of Astellas Pharma

    • Table Company Profile and Development Status of Novartis

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Novartis

    • Figure Sales and Growth Rate Analysis of Novartis

    • Figure Revenue and Market Share Analysis of Novartis

    • Table Product and Service Introduction of Novartis

    • Table Company Profile and Development Status of Synergy Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Synergy Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Synergy Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Synergy Pharmaceuticals

    • Table Product and Service Introduction of Synergy Pharmaceuticals

    • Table Company Profile and Development Status of Abbott Laboratories

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Abbott Laboratories

    • Figure Sales and Growth Rate Analysis of Abbott Laboratories

    • Figure Revenue and Market Share Analysis of Abbott Laboratories

    • Table Product and Service Introduction of Abbott Laboratories

    • Table Company Profile and Development Status of Valeant Pharmaceuticals International

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Valeant Pharmaceuticals International

    • Figure Sales and Growth Rate Analysis of Valeant Pharmaceuticals International

    • Figure Revenue and Market Share Analysis of Valeant Pharmaceuticals International

    • Table Product and Service Introduction of Valeant Pharmaceuticals International

    • Table Company Profile and Development Status of GlaxoSmithKline

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of GlaxoSmithKline

    • Figure Sales and Growth Rate Analysis of GlaxoSmithKline

    • Figure Revenue and Market Share Analysis of GlaxoSmithKline

    • Table Product and Service Introduction of GlaxoSmithKline

    • Table Company Profile and Development Status of Sucampo Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Sucampo Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Sucampo Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Sucampo Pharmaceuticals

    • Table Product and Service Introduction of Sucampo Pharmaceuticals

    • Table Company Profile and Development Status of Ardelyx

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Ardelyx

    • Figure Sales and Growth Rate Analysis of Ardelyx

    • Figure Revenue and Market Share Analysis of Ardelyx

    • Table Product and Service Introduction of Ardelyx

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US